How many people now have Neuralink brain implants?

Neuralink Corp has successfully implanted its N1 chip in seven patients as of March 2026, representing a 133% increase from the three recipients reported in late 2025. This enrollment milestone positions Elon Musk's brain-computer interface company ahead of its projected timeline for the PRIME (Precise Robotically Implanted Brain-Computer Interface) study, which received FDA approval in May 2023.

The seven implant recipients are all participating in Neuralink's first-in-human clinical trial evaluating the safety and efficacy of its wireless intracortical BCI system. Each patient has received the company's 1,024-electrode array implanted into the motor cortex, targeting individuals with tetraplegia who can demonstrate cursor control and digital device interaction through thought alone. The rapid enrollment suggests strong patient interest and streamlined surgical protocols at Neuralink's approved clinical sites.

This expansion makes Neuralink one of the largest active intracortical BCI trials by patient count, trailing only established academic consortiums like BrainGate Consortium, which has implanted over 30 patients across multiple studies since 2006. The milestone comes as the FDA continues evaluating multiple BCI companies for expanded clinical access.

Clinical Trial Progress and Safety Profile

The seven-patient cohort represents significant progress in Neuralink's PRIME study (NCT05849063), which originally targeted 22 participants across multiple years. According to sources familiar with the trial, all seven patients have successfully completed their initial surgical recovery periods without reported device-related serious adverse events.

Each participant received Neuralink's N1 implant through the company's R1 surgical robot, which precisely places 1,024 flexible electrode threads into cortical tissue. The surgical procedure typically takes 2-3 hours and involves creating a small craniotomy to access the motor cortex region responsible for hand and arm movement intentions.

The company has not disclosed specific performance metrics for all seven patients, but previous reports indicated the first two recipients achieved cursor control speeds exceeding 8 bits per second - competitive with other intracortical systems in clinical testing. This data point remains crucial for FDA evaluation of the system's therapeutic benefit.

Competitive Landscape and Market Position

Neuralink's seven-patient milestone places it in direct competition with several established BCI companies pursuing similar indications. Synchron has implanted its Stentrode endovascular device in over 10 patients across US and Australian trials, while Precision Neuroscience recently began human testing of its thin-film ECoG arrays.

The enrollment pace suggests Neuralink may be positioning for a pivotal trial application as early as 2027, though FDA requirements for Class III medical devices typically demand larger safety datasets. The company's wireless, fully-implantable design offers potential advantages over tethered systems used by academic researchers, but long-term biocompatibility remains unproven.

Industry observers note that Neuralink's high-profile status and Musk's public advocacy have likely contributed to strong patient recruitment. However, the ultimate clinical and commercial success will depend on demonstrating superior performance, safety, and durability compared to existing assistive technologies.

Regulatory Pathway and FDA Oversight

The FDA granted Neuralink Breakthrough Device Designation for its N1 system, expediting regulatory review for devices addressing unmet medical needs. This designation provides enhanced communication with FDA reviewers and prioritized evaluation of clinical data.

Current PRIME study endpoints focus on safety measures including infection rates, electrode impedance stability, and neural tissue response. Secondary endpoints evaluate cursor control accuracy, typing speed, and digital device interaction capabilities. The FDA will likely require at least 12 months of follow-up data from all participants before considering expanded access programs.

Neuralink must also demonstrate manufacturing scalability and quality controls for its complex electrode arrays and wireless electronics. The company has invested heavily in automated production facilities, but scaling from seven units to commercial volumes presents significant engineering challenges.

Future Implications for BCI Industry

The seven-patient milestone signals accelerating clinical activity across the intracortical BCI sector. Multiple companies are now in human testing phases, potentially creating a competitive landscape that could drive innovation and reduce costs. For patients with paralysis, this represents the first time multiple BCI options may become available within similar timeframes.

Neuralink's progress also influences investment flows into the broader BCI ecosystem. The company has raised over $600 million in funding, with recent valuations exceeding $5 billion based on private market transactions. This capital availability contrasts sharply with academic BCI programs operating on federal research grants.

The clinical success of multiple BCI companies could establish motor cortex interfaces as a viable therapeutic category, potentially attracting interest from major medical device manufacturers like Medtronic or Abbott. However, the path to commercial approval remains lengthy and uncertain for all current clinical-stage companies.

Key Takeaways

Neuralink has implanted seven patients with its N1 chip, more than doubling enrollment from three patients in late 2025
All seven recipients are participating in the FDA-approved PRIME study evaluating cursor control and digital device interaction
The enrollment pace positions Neuralink competitively against other clinical-stage BCI companies like Synchron and Precision Neuroscience
FDA Breakthrough Device Designation expedites regulatory review, but commercial approval remains years away
The seven-patient cohort represents one of the largest active intracortical BCI trials currently enrolling

Frequently Asked Questions

How many electrodes does each Neuralink implant contain? Each N1 implant contains 1,024 flexible electrode threads that record neural activity from individual neurons in the motor cortex. This electrode count exceeds most academic BCI systems but remains lower than next-generation arrays under development.

What conditions qualify patients for Neuralink's clinical trial? The PRIME study enrolls adults with tetraplegia due to spinal cord injury or amyotrophic lateral sclerosis (ALS) who retain stable motor cortex function. Participants must be at least one year post-injury and demonstrate stable medical conditions.

How long do patients keep the Neuralink implant? Current study protocols evaluate the implant for up to five years, though the actual duration depends on device performance and safety outcomes. Long-term biocompatibility data remains limited for all intracortical BCI systems.

When might Neuralink devices become commercially available? Commercial approval requires completion of pivotal trials, typically involving hundreds of patients across multiple years. Industry experts estimate 2028-2030 as the earliest possible timeline for FDA approval of intracortical BCI systems.

How does Neuralink compare to other BCI companies in clinical trials? Neuralink's seven patients trails Synchron's endovascular program but leads most intracortical competitors. BrainGate academic studies have implanted the most patients overall but use older, tethered technology requiring external hardware connections.